Haystack MRD® is an advanced tumor-informed minimal residual disease (MRD) test that detects ctDNA in blood with exceptional sensitivity and specificity.
Baltimore, MD
Joined June 2022
- Tweets552
- Following31
- Followers139
- Likes52
Going to #ESMO26 in Madrid? Interested in the advanced version of the technology featured in DYNAMIC? How about a #ctDNA test with zero false positives in clinical studies to date?
Visit Quest Diagnostics booth 8002 to learn about Haystack MRD®.
hubs.la/Q04BxKC40
#MRD
New peer-reviewed study! The Journal of Molecular Diagnostics recently published a Haystack MRD® clinical validation study using all samples with available DNA from the landmark DYNAMIC trial.
Check out our press release (hubs.la/Q04yV-SS0)
#ctDNA #MRD #oncology
Announcing the launch of a pilot program between Haystack MRD® by Quest Diagnostics® and OncoEMR®! Select providers now have access to Haystack MRD via OncoEMR MPI, bringing increased confidence in clinical decision-making. newsroom.questdiagnostics.co…
#ctDNA #MRD #oncology
We're proud to announce that Quest Diagnostics is now the largest clinical reference lab to integrate oncology tests in OncoEMR using the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature.
Read more: bit.ly/4brWiJV
A major milestone for Haystack MRD® by Quest Diagnostics®: New York State approval is another proof point for the quality and technological sophistication of our ctDNA test for solid tumors.
Read more: (hubs.la/Q04mY-4D0)
#ctDNA #MRD #oncology
Haystack MRD® by Quest Diagnostics® retweeted
A significant milestone for Haystack MRD® by Quest Diagnostics® and the patients we serve. With New York State approval, @HaystackMRD is now available in all 50 U.S. states, helping expand access to advanced cancer monitoring. newsroom.questdiagnostics.co…
Did you hear? Haystack MRD® is now approved by New York State. This approval is a prestigious regulatory milestone, underscoring Haystack MRD’s exceptional performance in detecting residual or recurrent cancer.
Learn more: (hubs.la/Q04mvsgY0)
#ctDNA #MRD #oncology
✅ Approved! We’re thrilled to announce Haystack MRD® by Quest Diagnostics® is approved by New York State. This broadens patient access to Haystack MRD, as it's now available in all 50 US states.
Check out our press release: (hubs.la/Q04mvWq90)
#ctDNA #MRD #oncology
One of our #ASCO26 posters (532) shows high concordance between ctDNA and ctHPV-DNA in HPV-driven oropharyngeal cancers, with ctDNA clearing faster than HPV in patients who were undergoing treatment. Learn more: hubs.la/Q04jjMXs0 #ctDNA #MRD
Heading to #ASCO26? Visit our poster on ptDNA in gastroesophageal cancer to see how next-generation sequencing is being used in innovative ways to advance personalized care. May 30, 9:00 AM-12:00 PM, poster 84. hubs.la/Q04jhSKk0 #ctDNA #MRD
Research collaborators are presenting new data at ASCO using Haystack MRD in 2 new disease types – gastric cancer and head and neck cancer.
Learn more about the abstracts being presented and meet Confidence, your Haystack Hero. hubs.la/Q04hX8_V0
#ASCO26 #ctDNA #MRD
Confidence changes how you move forward in cancer care. At #ASCO, see how Haystack MRD brings the clarity behind more confident clinical decisions. Visit the Quest Diagnostics booth 10109 to meet Confidence—the Haystack Hero for #ctDNA testing. Learn more: nam04.safelinks.protection.o…
See our poster presentation, “Real-world utilization of molecular residual disease testing in cancer care,” at #ONSCongress today: 11:25 AM–11:35 AM at Tower View Registration, Poster pavilion, Poster monitor 15. #ctDNA #MRD
Scientific session spotlight at the 2026 ONS Congress: “Real-world utilization of molecular residual disease testing in cancer care,” May 14 from 11:25 AM–11:35 AM at Tower View registration, Poster Pavilion, poster monitor 15. #ctDNA #MRD #ONSCongress
From clinical practice to clinical research, Haystack MRD® delivers exceptionally accurate ctDNA detection. See you at COA 2026 in Orlando. hubs.la/Q04dHP7q0 #COA2026 #MRD #ctDNA
Visit Quest Diagnostics® booth 808 at COA 2026 to learn how Haystack MRD® supports real-time treatment monitoring. hubs.la/Q04dHDly0 #COA2026 #MRD #ctDNA
We're excited to share that Haystack MRD® by Quest Diagnostics® was featured on CBS News Baltimore! Watch the story here:
hubs.la/Q04dP3zj0
#ctDNA #MRD #PrecisionOncology
Biopharma teams: Haystack MRD® can support your oncology trials through ctDNA-guided patient enrichment and stratification. Let’s connect at COA 2026. hubs.la/Q04dHDd10 #COA2026 #MRD #ctDNA
Oncology professionals—stop by Quest Diagnostics® booth 808 at the 2026 COA conference to explore ctDNA testing options with Haystack MRD®. hubs.la/Q04dHD5w0 #COA2026 #MRD #ctDNA
Haystack MRD® helps clinicians detect recurrence, make treatment decisions, and monitor treatment response. Let’s connect at #COA2026—Quest Diagnostics® booth 808. Learn more: hubs.la/Q04dhQCp0
New collaboration with City of Hope on a multi-year research program to evaluate how Haystack MRD can help guide patient management in multiple cancers by detecting #minimalresidualdisease and identifying recurrence earlier
hubs.la/Q04cmHgG0
#CityofHope #MRD #ctDNA